NLGN4X and breast cancer: Using a Kaplan–Meier analysis approach against a database of publicly available breast cancer samples, we demonstrated that higher NLGN4X (Fig 6) in ER+, PR+, Her+ and hormone receptor-negative basal-type breast cancer correlated significantly with a decrease in relapse-free survival and predicts advanced tumor malignancy and a poorer prognosis.